Neurosoft Bioelectronics has successfully secured $7.5 million in seed funding to enhance its innovative brain-computer interface (BCI) technology, elevating its total funding to over $20 million.
The funding round, led by Skybound Venture Capital and supported by various investors including IAG Capital Partners and Connecticut Innovations, aims to propel the company’s development of minimally invasive BCI systems. These systems are designed to monitor and interpret neural activity without the need for invasive procedures, leveraging soft-material engineering and AI analytics to create a comprehensive neural data platform.
Neurosoft's BCI technology specifically targets neurological conditions such as tinnitus and epilepsy, aiming to restore functionality for affected patients. The company also envisions expanding its applications to facilitate noninvasive communication between humans and machines in the future. The newly acquired funds will be instrumental in advancing human trials and commercializing the technology in the U.S.
In a strategic move to enhance its capabilities, Neurosoft has partnered with Science Corporation to utilize its neural recording tools and manufacturing resources, thereby accelerating the development process. As competition in the BCI sector intensifies, with notable players like Neuralink and INBRAIN Neuroelectronics, Neurosoft's advancements could play a significant role in shaping the future of human-machine interaction.